Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Sep 7;18(1):938-47.
doi: 10.2119/molmed.2011.00512.

Signaling to cardiac hypertrophy: insights from human and mouse RASopathies

Valentina Sala  1 , Simona Gallo, Christian Leo, Stefano Gatti, Bruce D Gelb, Tiziana Crepaldi
Affiliations
Review

Signaling to cardiac hypertrophy: insights from human and mouse RASopathies

Valentina Sala et al. Mol Med. .

Abstract

Cardiac hypertrophy is the heart's response to a variety of extrinsic and intrinsic stimuli, some of which might finally lead up to a maladaptive state. An integral part of the pathogenesis of the hypertrophic cardiomyopathy disease (HCM) is the activation of the rat sarcoma (RAS)/RAF/MEK (mitogen-activated protein kinase kinase)/MAPK (mitogen-activated protein kinase) cascade. Therefore, the molecular signaling involving RAS has been the subject of intense research efforts, particularly after the identification of the RASopathies. These constitute a class of developmental disorders caused by germline mutations affecting proteins contributing to the RAS pathway. Among other phenotypic features, a subset of these syndromes is characterized by HCM, prompting researchers and clinicians to delve into the chief signaling constituents of cardiac hypertrophy. In this review, we summarize current advances in the knowledge of the molecular signaling events involved in the pathogenesis of cardiac hypertrophy through work completed on patients and on genetically manipulated animals with HCM and RASopathies. Important insights are drawn from the recognition of parallels between cardiac hypertrophy and cancer. Future research promises to further elucidate the complex molecular interactions responsible for cardiac hypertrophy, possibly pointing the way for the identification of new specific targets for the treatment of HCM.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Schematic representation of RAS pathway and its correlation with RASopathies. A growth factor activates its RTK causing phosphorylation of tyrosines, which are bound by adapter proteins, SHC/GRB2 and GAB. These interact with the activators of RAS, SOS1 and SHP2, and induce the dissociation of GDP and binding of GTP. RAS-GTP activates a cascade of downstream kinases: the MAPK pathway. On the other hand, the inhibition of RAS signaling is mediated by GAPs: RASA1 and neurofibromin 1. The RASopathies are developmental pathologies due to mutations on genes encoding proteins of the RAS pathway. HCM is uncommon in NS and CFC patients. However, nearly all NS patients with mutated RAF1 develop HCM. PTPN11 (encoding SHP2) loss-of-function mutations were observed in the majority of LS patients who developed HCM. Mutations in RAF1 have also been identified in a small percentage of LS with HCM. CS patients harboring HRAS mutations consistently show cardiac hypertrophy. Light gray shading indicates the mutation-specific syndromes accompanied by HCM; dark gray shading indicates those syndromes in which cardiac hypertrophy is less common.
Figure 2
Figure 2
RAS Network: cross-links in hypertrophy. The cardiac hypertrophic response implicates signal transduction pathways initiated by ligand-stimulated membrane-bound receptors (RTKs, GPCRs) and biomechanical stress sensors (integrins). Various signaling effectors interact with the RAS/MEK/MAPK pathway. GPCR receptors activate RAS proteins through EPAC, induce release of internal Ca2+ stores and elicit pathological hypertrophy through calcineurin/NFAT. GPCRs also act through ERK activation. GSK3 kinase negatively regulates NFAT and, in turn, is inactivated by the PI3K-AKT pathway stimulated by RAS. Stimuli acting on integrins prompt cardiac hypertrophy through FAK activation and considerable cross-talk with RTK-mediated signaling. In addition, PAK regulates RAF1 activity. All these pathways converge on the modulation of transcriptional factors (MEF2, JUN and GATA4), which induce the expression of genes of the hypertrophic program.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Shih TY, Papageorge AG, Stokes PE, Weeks MO, Scolnick EM. Guanine nucleotide-binding and autophosphorylating activities associated with the p21src protein of Harvey murine sarcoma virus. Nature. 1980;287:686–91. - PubMed
    1. Raman M, Chen W, Cobb MH. Differential regulation and properties of MAPKs. Oncogene. 2007;26:3100–12. - PubMed
    1. Yoon S, Seger R. The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions. Growth Factors. 2006;24:21–44. - PubMed
    1. Hill JA, Olson EN. Mechanisms of disease: cardiac plasticity. New Engl J Med. 2008;358:1370–80. - PubMed
    1. Takai Y, Sasaki T, Matozaki T. Small GTP-binding proteins. Physiol Rev. 2001;81:153–208. - PubMed

Publication types